Home | Contact Us | Log In
(888) 789-6604
Report Stack
Advanced search
Account Detail 0 items in basket
Order History Total $
Saved Searches View Basket basket
Global Biosimilar Pipeline and Market Prospects: Addressing Production Complexities Through Risk Management and Quality by Design
Publication Date Mar 2017
Product Type Report
Single User License help $ 2995.00
Site User License help $ 5990.00
Corporate User License help $ 8985.00
 

Reportstack.com does not charge credit card fee, transaction charges, extra tax or VAT on any purchase.

GBI Research’s latest report Global Biosimilar Pipeline and Market Prospects: Overcoming Production Complexities Through Risk Management and Quality by Design provides an in-depth assessment of the current trends in the global biosimilars market, with a particular focus on manufacturing complexities and the strategies being implemented to overcome them. This report also assesses the state of the biosimilar R&D and commercial landscape through multilevel analytics that include data split by therapy area, stage of development, molecular target, clinical trials and company. Global revenue forecasts to 2022 for biosimilars with strong market potential, both in development and in the market, are provided.

The complex requirements of manufacturing biological drugs also apply to biosimilars, and these have been a significant barrier to the further expansion of the biosimilars market. A key challenge has been the knowledge gap under which biosimilars are developed, which arises from the fact that innovator product information remains proprietary and biosimilar manufacturers must adopt a reverse engineering process. Our new study assesses this and other significant manufacturing challenges, and how strategies based on quality initiatives and risk management can help address these issues.

Data analyses from our study show there will be enormous commercial opportunities for biosimilar developers over the coming years, given the number of high-revenue-generating biologics that will go off patent before 2020, and promising revenue forecasts for biosimilars in late-stage development. Information leveraged from our robust industry-leading database highlights a diverse number of biosimilars in the pipeline for a wide range of therapy areas, with several of these in the later stages of development. Case studies showcasing strategies adopted by leading pharmaceutical companies to compete in the biosimilars market are also provided.

Government support for biosimilars is increasing in key geographical markets, given the cost saving opportunities that these products represent for national healthcare budgets. Our study details current biosimilar regulatory frameworks and guidelines implemented in the US, Europe, Japan and China, recent updates regarding the key issue of interchangeability, and case studies of successful biosimilar approvals in recent years.

GBI Research conducted extensive research efforts in order to provide a comprehensive view of the global biosimilar market. This new report adds to our unique portfolio of trusted industry analyses that enable our clients to assess the most promising commercial areas in the market and exploit key business opportunities.
Scope

    Global biosimilar pipeline in 2017

    What is the distribution of pipeline biosimilars by stage of development?

    Which are the therapy areas set to benefit the most from biosimilar drugs in development?

    In biosimilar development, what are the most common molecular targets for key therapy areas?

    How many companies are currently involved in biosimilar drug development, which are the most active and what is the level of specialization across the development landscape?

    Global biosimilar clinical trials in 2017

    What was the volume of biosimilar clinical trials from 2006 to 2016, by therapy area and stage of development?

    What is the average biosimilar clinical trial size and duration across different stages of development, and across the immunology and oncology therapy areas?

    How much revenue will promising biosimilar drugs in the market, and in development, record to 2022?

    What are the key factors driving growth in the global biosimilars market?

    How important are the cost saving opportunities for national healthcare budgets?

    How much will biosimilar manufacturers benefit from the biologic drugs patent cliff?

    How does legislation regarding biosimilar interchangeability differ among key geographical markets?

    What are the factors restraining the growth of global biosimilar market?

    How do manufacturing challenges affect the market?

    What are the legal issues impacting the biosimilar market?

    How are competition and patient recruitment issues slowing growth in the market?

    What are the regulatory pathways for biosimilars in the US, Europe, Japan and China?

    Manufacturing processes for biosimilar drugs

    How does molecular weight and complexity pose a challenge to biosimilar production?

    What is the impact of environmental factors on production complexity?

    How significant is the knowledge gap in the process of manufacturing a biosimilar drug?

    What are the best practice guidelines and strategies to overcome production complexities?

    How do development timelines and costs differ between biologics and biosimilars?

    What is the impact of immunogenicity in the production process?

Reasons To Buy

    This report will allow you to:

    Gain insightful analyses and comprehensive understanding of the global biosimilar R&D and commercial landscape

    Assess biosimilar production processes, key issues and ways to mitigate development risk

    Understand the most important driving and restraining forces in the global biosimilars market

    Learn about biosimilar strategies being adopted by leading pharmaceutical companies.

    Understand the future outlook and prospects for biosimilar drugs


Table of Contents

1. Executive Summary

2. Introduction

2.1 Defining Biosimilars

2.2 Biosimilar Product Categories

2.3 Comparative Analysis: Biosimilars versus Generics

2.4 Biobetters versus Biosimilars

2.5 What Key Factors Are Driving the Need for Biosimilars?

3. Key Drivers of Growth in the Global Biosimilars Market

3.1 Cost Saving Potential

3.2 Biologics Patent Cliff

3.3 Increasing Clinical Evidence of Product Effectiveness

4. Key Barriers to Growth in the Global Biosimilars Market

4.1 Complexity of Expertise

4.2 Legal Issues

4.3 Biosimilar Interchangeability and Automatic Substitution

4.4 Patient Recruitment

4.5 Competition

5. Biosimilar Regulatory Frameworks in Key Geographies

5.1 EU

5.2 US

5.3 Japan

5.4 China

5.5 Case Studies of Successful Biosimilar Approvals in Key Markets

6. Biosimilar Manufacturing Process

6.1 Biologics

6.2 Biosimilars

6.3 GMP for large molecules

6.4 Biosimilars versus Biologics: Typical Development Timelines and Costs

7. Key Production Issues and Challenges

7.1 Molecular Weight and Complexity

7.3 Environmental Factors

7.4 Knowledge Gap

7.5 Immunogenicity

8. Approaches to Addressing Biosimilar Manufacturing Complexity

8.1 QbD

8.1.1 Reducing Biosimilar Development Risk through QbD

8.2 DoE

8.3 PAT

8.4 Safety and Risk Management

8.5 Production Best Practices

8.6 Alternative Expression System

9. Commercial Strategies for Biosimilars Adopted by Big Pharma

9.1 Big Pharma Biosimilar Strategies

9.2 Entry Strategies for Emerging Markets

9.3 Recommendations

10. Global Biosimilar Pipeline Analysis 2017

10.1 Global Biosimilar Pipeline by Stage of Development

10.2 Global Biosimilar Pipeline by Therapy Area

10.3 Global Biosimilar Pipeline by Molecular Target

10.4 Global Biosimilar Pipeline Company Analysis

10.5 Most Active Companies in the Global Biosimilar Pipeline: Volume of Products by Stage of Development

10.6 Most Active Companies in the Global Biosimilar Pipeline: Volume of Product by Therapy Area

10.7 Biosimilar Clinical Trials by Stage of Development: Average Size of Trials

10.8 Biosimilar Clinical Trials by Stage of Development: Average Trial Duration

10.9 Volume of Biosimilar Clinical Trials 2006–2016

10.10 Volume of Biosimilar Clinical Trials by Phase and Therapy Area

11. Global Biosimilar Market 2017–2022

11.1 Basaglar Global Sales Forecast 2015–2022

11.2 Inflectra Global Sales Forecast 2016–2022

11.3 Benepali Global Sales Forecast 2016–2022

11.4 Rituximab Biosimilar Global Sales Forecast 2019–2022

11.5 Trastuzumab Biosimilar Global Sales Forecast 2019–2022

11.6 Adalimumab Biosimilar Global Sales Forecast 2019–2022

11.7 Bevacizumab Biosimilar Global Sales Forecast 2019–2022

12. Future Outlook

13. Conclusion

Title Date Price
Europe Digital Camera Head for Endoscopes Industry 2016 Market Research Report
By QYResearch
The Europe Digital Camera Head for Endoscopes Industry 2016 Market Research Report is a professional and in-depth study on the current state of the Digital Camera Head for Endoscopes industry. The re ...Read More
Apr 2016 $3600.00
Global Dental Laboratory Handpieces Consumption 2016 Market Research Report
By QYResearch
The Global Dental Laboratory Handpieces Consumption 2016 Market Research Report is a professional and in-depth study on the current state of the Dental Laboratory Handpieces market. First, the report ...Read More
Jan 2016 $4000.00
Back to Report Store Home Cardiovascular Disorders Drug Development Pipeline Review, 2017
By GBI Research
Description Cardiovascular disease (CVD) covers a range of difference diseases and conditions affecting the heart and/or blood vessels. The most crucial risk factors for CVD are hypertension and dys ...Read More
Mar 2017 $3995.00
Back to Report Store Home Frontier Pharma: Chronic, Acute and Neuropathic Pain - GPCR and Nerve Growth Factor-based therapies offer strong potential in difficult-to-treat subtypes
By GBI Research
Pain, and in particular chronic pain, is a significant global health issue. While pain is not considered a disease in its own right, there is a growing body of evidence that substantiates chronic pain ...Read More
Aug 2016 $6995.00
Back to Report Store Home Frontier Pharma: Dermatology - Intracellular Signal Transducers and Cytokine Signaling Molecules Dominate Pipeline and First-in-Class Innovation
By GBI Research
Description Dermatology is a highly diverse therapy area that deals with diseases of the skin, hair and nails. Over 3,000 distinct dermatological conditions are thought to exist, ranging from rare a ...Read More
Jun 2017 $6995.00
Back to Report Store Home Frontier Pharma: Liver Cancer - Identifying and Commercializing First-in-Class Innovation
By GBI Research
Description Globally, liver cancer is the sixth most common cancer, but its poor prognosis makes it the second leading cause of cancer-related death (Globocan, 2012). Currently, the range of therapi ...Read More
Jun 2017 $6995.00
Back to Report Store Home Frontier Pharma: Rheumatoid Arthritis - Cytokine Mediators and Kinase Inhibitors Dominate First-in-Class Product Innovation
By GBI Research
Rheumatoid Arthritis (RA) is a chronic, progressive and currently incurable auto-immune disease that affects the joints, and is characterized by synovial inflammation and hyperplasia. It occurs when a ...Read More
Aug 2016 $6995.00
Back to Report Store Home Frontier Pharma: Versatile Innovation in Immunology - Large Therapy Area Pipeline with a High Degree of Repositioning Potential
By GBI Research
Immunology is a large therapy area characterized by disorders of the immune system – specifically an aberrant immune response against healthy tissues present in the body, leading to chronic or a ...Read More
Jan 2017 $6995.00
Back to Report Store Home Global Immunology Drugs Market to 2022-Increasing Prevalence, Repositioning Opportunities and Strong Uptake of Interleukin Receptor Inhibitors to Drive Growth
By GBI Research
Immunology is a therapy area characterized by disorders of the immune system, specifically an aberrant autoimmune response against healthy tissues in the body, leading to chronic or acute inflammation ...Read More
May 2017 $4995.00
Back to Report Store Home Innovation and Clinical Trial Tracking Factbook 2017: An Assessment of the Pharmaceutical Pipeline
By GBI Research
GBI Research’s latest report: “Innovation and Clinical Trial Tracking Factbook 2017: An Assessment of the Pharmaceutical Pipeline” is a comprehensive, granular analysis of the 25,522 ...Read More
May 2017 $2995.00

  * Required field
Name *
E-mail *
Telephone 
Company *
Country *
Query 
 
   

Published By :  GBI Research

For support please
contact:
US Toll Free
+1 888-789-6604
Asia Pacific
+91-9893555190
 
 
To receive alerts about
an update, future offers and discounts on this report, signup here.
Email ID
 

Companies


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Countries


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z